Fernanda Bueno

486 total citations
20 papers, 337 citations indexed

About

Fernanda Bueno is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Epidemiology. According to data from OpenAlex, Fernanda Bueno has authored 20 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Surgery and 3 papers in Epidemiology. Recurrent topics in Fernanda Bueno's work include Thyroid Cancer Diagnosis and Treatment (20 papers), Thyroid and Parathyroid Surgery (7 papers) and Neuroendocrine Tumor Research Advances (3 papers). Fernanda Bueno is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (20 papers), Thyroid and Parathyroid Surgery (7 papers) and Neuroendocrine Tumor Research Advances (3 papers). Fernanda Bueno collaborates with scholars based in Argentina, Uruguay and United States. Fernanda Bueno's co-authors include Fabián Pitoia, Erika Abelleira, R. Michael Tuttle, Fernando Jerkovich, A Schmidt, Hugo Nièpomniszcze, Hernán Tala, Robert J. Marlowe, Eduardo Faure and Gabriela Brenta and has published in prestigious journals such as Thyroid, Endocrine and Clinical Nuclear Medicine.

In The Last Decade

Fernanda Bueno

19 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fernanda Bueno Argentina 11 315 151 65 46 45 20 337
Erika Abelleira Argentina 11 322 1.0× 152 1.0× 68 1.0× 43 0.9× 44 1.0× 27 352
Zbigniew Puch Poland 9 335 1.1× 179 1.2× 50 0.8× 79 1.7× 23 0.5× 20 362
Andrea Di Santo Italy 5 264 0.8× 99 0.7× 77 1.2× 14 0.3× 42 0.9× 7 297
Aya Ebina Japan 9 438 1.4× 285 1.9× 83 1.3× 44 1.0× 90 2.0× 23 492
Simone M. Dustin United States 6 269 0.9× 188 1.2× 50 0.8× 23 0.5× 25 0.6× 8 323
Gabriela Franco Mourão Brazil 12 447 1.4× 296 2.0× 40 0.6× 57 1.2× 24 0.5× 36 466
Osamu Fukuoka Japan 8 219 0.7× 201 1.3× 34 0.5× 43 0.9× 74 1.6× 18 332
Massimiliano Siracusa Italy 10 195 0.6× 97 0.6× 13 0.2× 60 1.3× 37 0.8× 20 270
Marcin Zeman Poland 6 79 0.3× 64 0.4× 23 0.4× 8 0.2× 85 1.9× 25 185
Alexis Vrachimis Switzerland 8 133 0.4× 34 0.2× 10 0.2× 92 2.0× 37 0.8× 13 211

Countries citing papers authored by Fernanda Bueno

Since Specialization
Citations

This map shows the geographic impact of Fernanda Bueno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernanda Bueno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernanda Bueno more than expected).

Fields of papers citing papers by Fernanda Bueno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernanda Bueno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernanda Bueno. The network helps show where Fernanda Bueno may publish in the future.

Co-authorship network of co-authors of Fernanda Bueno

This figure shows the co-authorship network connecting the top 25 collaborators of Fernanda Bueno. A scholar is included among the top collaborators of Fernanda Bueno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernanda Bueno. Fernanda Bueno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bueno, Fernanda, et al.. (2023). Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience. Endocrine. 80(1). 134–141. 9 indexed citations
2.
3.
Abelleira, Erika, et al.. (2021). Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment. Archives of Endocrinology and Metabolism. 65(3). 315–321. 3 indexed citations
4.
Bueno, Fernanda, et al.. (2021). Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic. Archives of Endocrinology and Metabolism. 65(2). 242–247. 4 indexed citations
5.
Abelleira, Erika, et al.. (2020). Thyroid cancer in the Era of COVID-19. Endocrine. 70(1). 1–5. 16 indexed citations
6.
Abelleira, Erika, et al.. (2020). Role of 18F-FDG-PET/CT in patients with differentiated thyroid cancer with biochemical incomplete or indeterminate response to treatment. Endocrinología Diabetes y Nutrición. 67(8). 517–524. 5 indexed citations
7.
Jerkovich, Fernando, et al.. (2020). Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina. Endocrine. 69(1). 142–148. 24 indexed citations
8.
Abelleira, Erika, et al.. (2020). Role of 18F-FDG-PET/CT in patients with differentiated thyroid cancer with biochemical incomplete or indeterminate response to treatment. Endocrinología Diabetes y Nutrición (English ed ). 67(8). 517–524.
9.
Bueno, Fernanda, et al.. (2019). Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer. Endocrine. 67(2). 387–396. 12 indexed citations
10.
Pitoia, Fabián, A Schmidt, Fernanda Bueno, Erika Abelleira, & Fernando Jerkovich. (2018). Rare complications of multikinase inhibitor treatment. Archives of Endocrinology and Metabolism. 62(6). 636–640. 6 indexed citations
11.
12.
Abelleira, Erika, et al.. (2017). Riesgo dinámico en pacientes con cáncer diferenciado de tiroides no ablacionados. 54(2). 69–75. 2 indexed citations
13.
14.
Pitoia, Fabián, Fernando Jerkovich, A Schmidt, et al.. (2015). Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence. Thyroid. 25(11). 1235–1242. 34 indexed citations
15.
Pitoia, Fabián, et al.. (2015). Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome. Archives of Endocrinology and Metabolism. 59(4). 343–346. 15 indexed citations
16.
Pitoia, Fabián, et al.. (2014). Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer. Endocrine. 48(3). 894–901. 12 indexed citations
17.
18.
Pitoia, Fabián, et al.. (2013). Biochemical persistence in thyroid cancer: is there anything to worry about?. Endocrine. 46(3). 532–537. 22 indexed citations
19.
20.
Pitoia, Fabián, Robert J. Marlowe, Erika Abelleira, et al.. (2012). Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer. Journal of Thyroid Research. 2012. 1–8. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erika Abelleira Breakdown of academic impact, for papers by Zbigniew Puch Breakdown of academic impact, for papers by Andrea Di Santo Breakdown of academic impact, for papers by Aya Ebina Breakdown of academic impact, for papers by Simone M. Dustin Breakdown of academic impact, for papers by Gabriela Franco Mourão Breakdown of academic impact, for papers by Osamu Fukuoka Breakdown of academic impact, for papers by Massimiliano Siracusa Breakdown of academic impact, for papers by Marcin Zeman Breakdown of academic impact, for papers by Alexis Vrachimis
Rankless by CCL
2026